Fundraising FoxVersant Ventures — 2021 Investments
9 investments dated 2021 · listed companies and verified rows first · show all
Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.
AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US
Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in
BoardToshikazu Ban(Director)
Board seatCarlo Rizzuto· per SEC Form D
Co-investorsLifeSci Venture PartnersRA CapitalCasdin Capital
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill Ventures+4 more
Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
BiotechSouth San Francisco, US
Josh Lehrer(Executive Officer, Director)Katherine Stultz(Executive Officer)inPhilip Gutry(Executive Officer)Evert Schimmelpennink(Chief Executive Officer, President, Secretary, and Director)Daniel Chevallard(Chief Financial Officer)Shawn Olsson(Chief Commercial Officer)in
Co-investorsSamsara BioCapital
iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.
BiotechHealthtechMedical Devices
James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)inPaul Firuta(COO)inAlex Monteith(Chief Business Officer)David Garrett(CFO)inGabriel M. Cohn(Chief Medical Officer)in
Co-investorsOrbiMedLYFE Capital
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)David Allison(Director)inKeno Gutierrez(Director)in
Co-investors5AM VenturesNovartis Venture FundRoche Venture FundBioGeneration VenturesWestlake Village BioPartners
Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function.
BiotechDeep TechHealthtechNew York City, US
Henry Colecraft(Co-Founder & Chair of SAB)Scott Kanner(Co-Founder & Scientific Advisor)inEddine Saiah(CEO and President)in
Co-investorsNew Enterprise Associates (NEA)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Graphite Bio, Inc.Capsida BiotherapeuticsTentarix Biotherapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.